"Furthermore, although the reviewed studies have consistently shown the cardioprotective effects of SGLT2 inhibitors against cancer treatment–related cardiotoxicity in tumor-free models, none has yet concurrently demonstrated the cardioprotective and the anticancer effects of SGLT2 inhibitors in tumor-bearing model"
Definitely a space to watch, the SGLT2s are ubiquitous in cardiorenal disease and form part of the fundamental 4 pillars of heart failure treatments along with the ARNIs, beta-blockers and MRAs. They will get great physician buy-in if they can demonstrate cardioprotection in an RCT.
Of course the holy-grail is cardioprotection AND anti-cancer synergy which is yet to be proven in SGLT2s but this could pose a threat to bisantrene if proven.
Gret find @HeyLine
Cardioprotection thread, page-557
-
- There are more pages in this discussion • 315 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.54 |
Change
-0.015(0.97%) |
Mkt cap ! $261.5M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.55 | $1.50 | $111.4K | 73.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 1400 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |